360 related articles for article (PubMed ID: 22309083)
1. Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies.
Paulis G; Brancato T
Inflamm Allergy Drug Targets; 2012 Feb; 11(1):48-57. PubMed ID: 22309083
[TBL] [Abstract][Full Text] [Related]
2. Peironimev-Plus® in the treatment of chronic inflammation of tunica albuginea (Peyronie's disease). results of a controlled study.
Paulis G; Cavallini G; Brancato T; Alvaro R
Inflamm Allergy Drug Targets; 2013 Feb; 12(1):61-7. PubMed ID: 23004005
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.
Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D
BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734
[TBL] [Abstract][Full Text] [Related]
4. Medical management of Peyronie's disease.
Hellstrom WJ
J Androl; 2009; 30(4):397-405. PubMed ID: 18974422
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Management of Peyronie's Disease.
Trost LW; Gur S; Hellstrom WJ
Drugs; 2007; 67(4):527-45. PubMed ID: 17352513
[TBL] [Abstract][Full Text] [Related]
6. Management of Peyronie's disease--a review.
Tunuguntla HS
World J Urol; 2001 Aug; 19(4):244-50. PubMed ID: 11550782
[TBL] [Abstract][Full Text] [Related]
7. Could plaque excision surgery with sis graft induce a new fibrotic reaction in la Peyronie's disease patients?
Rolle L; Tamagnone A; Bollito E; Ceruti C; Timpano M; Negro CL; Galletto E; Fontana D
Arch Ital Urol Androl; 2007 Dec; 79(4):167-9. PubMed ID: 18303735
[TBL] [Abstract][Full Text] [Related]
8. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.
Valente EG; Vernet D; Ferrini MG; Qian A; Rajfer J; Gonzalez-Cadavid NF
Nitric Oxide; 2003 Dec; 9(4):229-44. PubMed ID: 14996430
[TBL] [Abstract][Full Text] [Related]
9. EAU guidelines on penile curvature.
Hatzimouratidis K; Eardley I; Giuliano F; Hatzichristou D; Moncada I; Salonia A; Vardi Y; Wespes E;
Eur Urol; 2012 Sep; 62(3):543-52. PubMed ID: 22658761
[TBL] [Abstract][Full Text] [Related]
10. Microstructural disorders of tunica albuginea in patients affected by Peyronie's disease with or without erection dysfunction.
Iacono F; Barra S; De Rosa G; Boscaino A; Lotti T
J Urol; 1993 Dec; 150(6):1806-9. PubMed ID: 8230510
[TBL] [Abstract][Full Text] [Related]
11. A new biopsy technique to investigate Peyronie's disease associated histologic alterations: results with two different forms of therapy.
Mirone V; Imbimbo C; Palmieri A; Longo N; Fusco F; Tajana G
Eur Urol; 2002 Sep; 42(3):239-44; discussion 244. PubMed ID: 12234508
[TBL] [Abstract][Full Text] [Related]
12. A new mouse model of Peyronie's disease: an increased expression of hypoxia-inducible factor-1 target genes during the development of penile changes.
Lucattelli M; Lunghi B; Fineschi S; Mirone V; d'Emmanuele di Villa Bianca R; Longo N; Imbimbo C; De Palma R; Sorrentino R; Lungarella G; Cirino G
Int J Biochem Cell Biol; 2008; 40(11):2638-48. PubMed ID: 18599338
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.
Gonzalez-Cadavid NF; Rajfer J
Nat Rev Urol; 2010 Apr; 7(4):215-21. PubMed ID: 20212516
[TBL] [Abstract][Full Text] [Related]
14. Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options.
Gur S; Limin M; Hellstrom WJ
Expert Opin Pharmacother; 2011 Apr; 12(6):931-44. PubMed ID: 21405946
[TBL] [Abstract][Full Text] [Related]
15. Experimental models of Peyronie's disease. Implications for new therapies.
Gonzalez-Cadavid NF; Rajfer J
J Sex Med; 2009 Feb; 6(2):303-13. PubMed ID: 19138365
[TBL] [Abstract][Full Text] [Related]
16. A critical analysis of nonsurgical treatment of Peyronie's disease.
Hauck EW; Diemer T; Schmelz HU; Weidner W
Eur Urol; 2006 Jun; 49(6):987-97. PubMed ID: 16698449
[TBL] [Abstract][Full Text] [Related]
17. Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models.
Ilg MM; Mateus M; Stebbeds WJ; Milenkovic U; Christopher N; Muneer A; Albersen M; Ralph DJ; Cellek S
Eur Urol; 2019 Feb; 75(2):329-340. PubMed ID: 30344087
[TBL] [Abstract][Full Text] [Related]
18. How curved is too curved? The severity of penile deformity may predict sexual disability among men with Peyronie's disease.
Walsh TJ; Hotaling JM; Lue TF; Smith JF
Int J Impot Res; 2013 May; 25(3):109-12. PubMed ID: 23344164
[TBL] [Abstract][Full Text] [Related]
19. Peyronie's disease: epidemiology, diagnosis, and management.
Miner MM; Seftel AD
Curr Med Res Opin; 2014 Jan; 30(1):113-20. PubMed ID: 24040888
[TBL] [Abstract][Full Text] [Related]
20. [Review of Peyronie's disease].
Stein A; Dekel Y
Harefuah; 2012 Nov; 151(11):638-40, 653. PubMed ID: 23367736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
